For the year ending 2025-12-31, URGN has $200,455K in assets. $305,929K in debts. $110,745K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 110,745 | |||
| Marketable securities | 9,711 | |||
| Restricted cash | 1,350 | |||
| Accounts receivable, net | 33,082 | |||
| Inventories | 16,464 | |||
| Prepaid expenses and other current assets | 14,672 | |||
| Total current assets | 186,024 | |||
| Property and equipment, gross | 5,224 | |||
| Less accumulated depreciation and amortization | 4,587 | |||
| Property and equipment, net | 637 | |||
| Restricted deposit | 177 | |||
| Right-of-use assets, operating and finance leases | 8,456 | |||
| Marketable securities | 0 | |||
| Other non-current assets | 5,161 | |||
| Total assets | 200,455 | |||
| Accounts payable and accrued expenses | 27,717 | |||
| Employee related accrued expenses | 13,516 | |||
| Other liabilities, current | 5,185 | |||
| Total current liabilities | 46,418 | |||
| Prepaid forward obligation | 127,276 | |||
| Long-term debt | 122,210 | |||
| Lease, liabilities, noncurrent | 6,122 | |||
| Uncertain tax positions liability | 3,903 | |||
| Total liabilities | 305,929 | |||
| Ordinary shares, nis 0.01 par value 100,000,000 shares authorized at december 31, 2025 and 2024 48,350,272 and 42,231,746 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 133 | |||
| Additional paid-in capital | 854,090 | |||
| Accumulated deficit | -959,716 | |||
| Accumulated other comprehensive income | 19 | |||
| Total shareholders' deficit | -105,474 | |||
| Total liabilities and shareholders' deficit | 200,455 | |||
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)